TABLE 3.
Radezolid and linezolid minimum inhibitory concentrations (MICs) decreased in the presence of PAβN.
| Isolates | MIC (mg/L) | |||
| LZD | LZD + PAβN | RZD | RZD + PAβN | |
| ATCC29212-0 | 2 | 2 | 0.25 | 0.25 |
| ATCC29212-6 | 8 | 4 | 0.25 | 0.25 |
| ATCC29212-10 | 16 | 4 | 0.5 | 0.25 |
| ATCC29212-18 | 64 | 8 | 1 | 0.25 |
| ATCC29212-22 | 128 | 32 | 1 | 0.5 |
| ATCC29212-27 | 256 | 32 | 1 | 0.5 |
| ATCC29212-47 | 256 | 64 | 8 | 2 |
| OG1RF-0 | 2 | 2 | 0.25 | 0.25 |
| OG1RF-5 | 8 | 2 | 0.25 | 0.25 |
| OG1RF-8 | 16 | 4 | 1 | 0.25 |
| OG1RF-18 | 64 | 8 | 4 | 0.5 |
| OG1RF-25 | 128 | 16 | 4 | 1 |
| OG1RF-30 | 256 | 16 | 4 | 1 |
| OG1RF-55 | 256 | 32 | 8 | 2 |
RZD, radezolid; LZD, linezolid; PAβN, Phe-Arg-β-naphthylamide (20 mg/L).